BR112014010263A2 - método de preparação do acetato de ulipristal e intermediário deste - Google Patents

método de preparação do acetato de ulipristal e intermediário deste

Info

Publication number
BR112014010263A2
BR112014010263A2 BR112014010263A BR112014010263A BR112014010263A2 BR 112014010263 A2 BR112014010263 A2 BR 112014010263A2 BR 112014010263 A BR112014010263 A BR 112014010263A BR 112014010263 A BR112014010263 A BR 112014010263A BR 112014010263 A2 BR112014010263 A2 BR 112014010263A2
Authority
BR
Brazil
Prior art keywords
formula
compound
ulipristal acetate
preparation
reaction
Prior art date
Application number
BR112014010263A
Other languages
English (en)
Other versions
BR112014010263B1 (pt
Inventor
Luo Junzhi
Qian Mingxia
Luo Xun
Yan Yimin
Sun Yongqiang
Tu Yongrui
Wang Zhaojun
Original Assignee
Changzhou No 4 Pharmaceutical Factory Co Ltd
Utopharm (Shanghai) Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Changzhou No 4 Pharmaceutical Factory Co Ltd, Utopharm (Shanghai) Co Ltd filed Critical Changzhou No 4 Pharmaceutical Factory Co Ltd
Publication of BR112014010263A2 publication Critical patent/BR112014010263A2/pt
Publication of BR112014010263B1 publication Critical patent/BR112014010263B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0077—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom
    • C07J41/0083—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom substituted in position 11-beta by an optionally substituted phenyl group not further condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/004—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa
    • C07J7/0045—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/001—Oxiranes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/005—Ketals
    • C07J21/006—Ketals at position 3
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

resumo método de preparação do acetato de ulipristal e intermediário deste é fornecido um método no campo químico de preparação de acetato de ulipristal (composto i), um novo intermediário chave (composto da fórmula iv) para preparar o acetato de ulipristal e o intermediário chave. surpreendentemente foi encontrada na presente invenção que o novo intermediário da fórmula iv facilita a reação com metil lítio ou um reagente de grignard metila; o grupo protetor pode ser facilmente removido após a reação, com poucas reações laterais e tratamento simples do intermediário; o reagente utilizado está prontamente disponível, com baixo custo e alto rendimento; um composto de fórmula iii é primeiramente preparado para um intermediário de fórmula iv e o intermediário é então preparado para um composto de fórmula v; o rendimento total das duas etapas é tão elevado quanto 75%, com a pureza do produto maior do que 98%. r na fórmula é conforme definido na especificação. 1/1
BR112014010263-5A 2011-11-01 2012-07-12 Método de preparação do acetato de ulipristal e intermediário deste BR112014010263B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201110339479.8 2011-11-01
CN201110339479.8A CN102516345B (zh) 2011-11-01 2011-11-01 醋酸乌利司他及其关键中间体的制备方法
PCT/CN2012/000952 WO2013063859A1 (zh) 2011-11-01 2012-07-12 醋酸乌利司他的制备方法及其中间体

Publications (2)

Publication Number Publication Date
BR112014010263A2 true BR112014010263A2 (pt) 2017-04-18
BR112014010263B1 BR112014010263B1 (pt) 2021-11-03

Family

ID=46287461

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014010263-5A BR112014010263B1 (pt) 2011-11-01 2012-07-12 Método de preparação do acetato de ulipristal e intermediário deste

Country Status (14)

Country Link
US (1) US9163058B2 (pt)
EP (1) EP2774933B1 (pt)
JP (1) JP5913599B2 (pt)
CN (1) CN102516345B (pt)
AU (1) AU2012331996B2 (pt)
BR (1) BR112014010263B1 (pt)
CA (1) CA2851399C (pt)
ES (1) ES2669052T3 (pt)
HU (1) HUE037674T2 (pt)
IN (1) IN2014CN02562A (pt)
MX (1) MX343774B (pt)
PL (1) PL2774933T3 (pt)
RU (1) RU2624007C2 (pt)
WO (1) WO2013063859A1 (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102516345B (zh) * 2011-11-01 2014-11-26 上海优拓医药科技有限公司 醋酸乌利司他及其关键中间体的制备方法
CN103073612B (zh) * 2013-02-04 2015-11-04 山东大学 醋酸乌利司他关键中间体的制备方法
CN103145788B (zh) * 2013-03-25 2015-08-19 浙江仙琚制药股份有限公司 醋酸优力司特关键中间体的制备方法
HU230319B1 (hu) 2013-10-01 2016-01-28 Richter Gedeon Nyrt. Ipari eljárás szteroid hatóanyagok előállítására
CN104558089A (zh) * 2013-10-25 2015-04-29 上海医药工业研究院 一种3-(亚乙二氧基)-17β-氰基-17α-羟基-雌-5(10)，9(11)-二烯的制备方法
CN103641881A (zh) * 2013-11-22 2014-03-19 湖南新合新生物医药有限公司 乌利司他中间体的制备方法
CN103601785A (zh) * 2013-11-25 2014-02-26 四川大学 一种醋酸优力斯特新的合成方法
CN104774231A (zh) * 2014-01-13 2015-07-15 上海医药工业研究院 17α-羟基-19-去甲孕甾-4,9-二烯-3,20-二酮的制备工艺
CN105294808B (zh) * 2015-09-28 2017-08-25 国家卫生计生委科学技术研究所 醋酸乌利司他晶g型物质及制备方法和其组合物与用途
CN105237607B (zh) * 2015-10-29 2018-10-02 国家卫生计生委科学技术研究所 醋酸乌利司他晶k型物质及制备方法和其组合物与用途
CN105669810B (zh) * 2016-02-19 2017-05-10 常州市第四制药厂有限公司 一种醋酸乌利司他的杂质及其制备和检测方法
CN105566432B (zh) * 2016-02-19 2017-11-03 常州四药制药有限公司 一种醋酸乌利司他的杂质及其制备和检测方法
CN105566431B (zh) * 2016-02-19 2017-11-24 常州市第四制药厂有限公司 一种醋酸乌利司他的杂质及其制备和检测方法
CN105669819B (zh) * 2016-03-23 2017-06-23 浙江仙琚制药股份有限公司 制备醋酸优力司特双缩酮异构体的方法
CN106866778A (zh) * 2017-04-25 2017-06-20 广西万德药业有限公司 一种5(10)位α环氧甾族化合物的合成方法
CN108070016B (zh) * 2017-12-29 2020-07-07 广西万德药业有限公司 甾体环氧异构体的循环利用方法
CN108558981B (zh) * 2018-05-08 2020-05-08 浙江仙琚制药股份有限公司 制备双缩酮的方法
JP7303618B2 (ja) * 2018-10-05 2023-07-05 日本精化株式会社 スフィンゴリン脂質前駆体及びその製造方法、並びに、スフィンゴリン脂質の製造方法
CN110256519B (zh) * 2019-05-23 2021-06-08 江苏联环药业股份有限公司 一锅法制备醋酸乌利司他的方法
CN111018935A (zh) * 2019-12-31 2020-04-17 浙江仙居君业药业有限公司 一种醋酸乌利斯他中间体的合成方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0263569B1 (en) * 1986-10-10 1992-12-09 Roussel-Uclaf 9-alpha-hydroxysteroids, process for their preparation and process for the preparation of the corresponding 9(11)-dehydro-derivatives.
US4954490A (en) * 1988-06-23 1990-09-04 Research Triangle Institute 11 β-substituted progesterone analogs
US5929262A (en) * 1995-03-30 1999-07-27 The United States Of America As Represented By The Department Of Health And Human Services Method for preparing 17α-acetoxy-11β-(4-N, N-dimethylaminophyl)-19-Norpregna-4,9-diene-3, 20-dione, intermediates useful in the method, and methods for the preparation of such intermediates
US6020328A (en) * 1998-03-06 2000-02-01 Research Triangle Institute 20-keto-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
DE60134126D1 (de) * 2000-03-17 2008-07-03 Us Gov Health & Human Serv 17-alpha-substituierte-11-beta-substituierte-4-aryl und 21-substituierte 19-norpregnadienedione mit antigestagener aktivität
EP1613640A4 (en) * 2003-02-28 2010-05-19 Us Gov Health & Human Serv PROCESS FOR PREPARING 17 ALPHA-ACETOXY-11 BETA- (4-N, N-DIMETHYLAMINOPHENYL) -19-NORPREGNA-4,9-DIENE-3,20-DION, INTERMEDIATE PRODUCTS AND METHOD OF MANUFACTURING THESE INTERMEDIATE PRODUCTS
US20050288521A1 (en) * 2004-06-29 2005-12-29 Phytogen Life Sciences Inc. Semi-synthetic conversion of paclitaxel to docetaxel
HU227112B1 (hu) * 2006-06-14 2010-07-28 Richter Gedeon Nyrt Ipari eljárás 17-alfa-acetoxi-11-béta-[4-(N,N-dimetil-amino)-fenil]-19-norpregna-4,9-dién-3,20-dion elõállítására és új intermedierek az eljáráshoz
HU228636B1 (en) * 2007-06-27 2013-04-29 Richter Gedeon Nyrt Industrial method for the synthesis of 17-acetoxy-11betha-4[-(dimethylamino)-phenyl]-21-methoxy-19-norpregna-4,9-dien-3,20-dione and the key intermediates of the process
CN102516345B (zh) 2011-11-01 2014-11-26 上海优拓医药科技有限公司 醋酸乌利司他及其关键中间体的制备方法

Also Published As

Publication number Publication date
JP2014528459A (ja) 2014-10-27
WO2013063859A1 (zh) 2013-05-10
EP2774933A1 (en) 2014-09-10
BR112014010263B1 (pt) 2021-11-03
AU2012331996B2 (en) 2015-04-23
CN102516345B (zh) 2014-11-26
MX2014005245A (es) 2014-08-22
RU2624007C2 (ru) 2017-06-30
ES2669052T3 (es) 2018-05-23
CN102516345A (zh) 2012-06-27
EP2774933B1 (en) 2018-02-21
IN2014CN02562A (pt) 2015-08-07
RU2014120908A (ru) 2015-12-10
JP5913599B2 (ja) 2016-04-27
AU2012331996A1 (en) 2014-05-15
MX343774B (es) 2016-11-23
US9163058B2 (en) 2015-10-20
CA2851399C (en) 2019-06-25
US20140296510A1 (en) 2014-10-02
HUE037674T2 (hu) 2018-09-28
CA2851399A1 (en) 2013-05-10
PL2774933T3 (pl) 2018-08-31
EP2774933A4 (en) 2015-07-08

Similar Documents

Publication Publication Date Title
BR112014010263A2 (pt) método de preparação do acetato de ulipristal e intermediário deste
BR112017027831A2 (pt) derivados de hidroxiácido, um processo para sua preparação e composições farmacêuticas contendo-os
MY189544A (en) Binding molecules for bcma and cd3
BR112014018756A8 (pt) Processo para preparo de etil éster de ácido n-(4-ciclo-hexil-3-trifluorometil-benziloxi)-acetimídico
BR112012020983A2 (pt) processo para a preparação de derivados isoxazolina
CO6630189A2 (es) Compuestos heterocíclicos de nitrógeno útiles como inhibidores de pde10
DOP2014000204A (es) Compuestos de heterociclilo como inhibidores de mek
BR112014007193A2 (pt) derivados de pirazoloquinolinona, preparação dos mesmos e uso terapêutico dos mesmos
NZ613807A (en) Phosphorus-containing group-substituted quinoline, its preparation process, medical composition containing the compound and application
BR112015031913A2 (pt) processo para a fabricação de amino-benzoxazinonas 4-propargilatadas e sua utilização
BR112014014881A2 (pt) método para isolar ácido carboxílico a partir de solução aquosa
BR112015009395A2 (pt) processo para preparação de derivados do ácido biliar
BR112012032244A2 (pt) processo para preparar derivados de antranilamida com tetrazole-substituído e polimorfos cristalinos novos e derivados destes
BR112013020384A2 (pt) métodos e sistemas para o revestimento de substratos granulares
PE20151652A1 (es) Proceso e intermedios para preparar un medicamento
BR112013011593A2 (pt) cristal de derivado de morfinan 7-carbamoíla-6,7-insaturada e método para produzir o mesmo
BR112013016578A2 (pt) processo para preparar metilmercaptopropionaldeídeo
IN2014DN02166A (pt)
MX2010009860A (es) Sintesis total de salinosporamida a y sus analogos.
PH12014502453B1 (en) Process for preparation of optically pure and optionally substituted 2-(1-hydroxy-alkyl)- chromen-4-one derivatives and their use in preparing pharmaceuticals
BR112013024257A2 (pt) método para reduzir ou prevenir a incrustação em um processo de produção de ácido fosfórico em processo a úmido
BR112015014583B1 (pt) compostos, processo para a preparação de compostos, compostos intermediários, composição, usos de um composto de fórmula i e método para combater fungos nocivos
MX347075B (es) Colorantes acidos de trisazo.
BR112015015229A8 (pt) processo para a preparação de um composto da fórmula, e, composto
BR112014027994A2 (pt) métodos de cristalização para purificação de anticorpos monoclonais

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: AS CLASSIFICACOES ANTERIORES ERAM: C07J 41/00 , C07J 21/00 , C07J 75/00

Ipc: A61K 31/57 (2006.01), C07J 21/00 (2006.01), C07J 7

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 12/07/2012, OBSERVADAS AS CONDICOES LEGAIS.